Medical Treatment of Hyperthyroidism: State of the Art

被引：33

作者：

Fumarola, A. ^{[1
]}

Di Fiore, A. ^{[1
]}

Dainelli, M. ^{[1
]}

Grani, G. ^{[1
]}

Calvanese, A. ^{[1
]}

机构：

[1] Sapienza Univ Roma, Dipartimento Med Sperimentale, UOC Endocrinol A, I-00161 Rome, Italy

来源：

EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES | 2010年 / 118卷 / 10期

关键词：

Hyperthyroidism; Graves' disease; Thionamides; MONOCLONAL-ANTIBODY RITUXIMAB; B-LYMPHOCYTE DEPLETION; THYROID FOLLICULAR CELLS; GRAVES-DISEASE; ANTITHYROID DRUGS; TREATMENT DURATION; INDUCED AGRANULOCYTOSIS; ULCERATIVE-COLITIS; I-131; THERAPY; PROPYLTHIOURACIL;

D O I：

10.1055/s-0030-1253420

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Methimazole (MMI) and propylthiouracil (PTU) are the main antithyroid drugs used for hyperthyroidism. They inhibit the synthesis of thyroid hormone at various levels and are used as the primary treatment for hyperthyroidism or as a preparation before radioiodine therapy or thyroidectomy. MMI is the drug of choice because of its widespread availability, longer half-life and small number of severe side effects. Drugs of second choice are potassium perchlorate, beta blockers, iodine, lithium carbonate and glucocorticoids. Rituximab, a monoclonal antibody directed against human CD20, was recently proposed as a biological therapy for cases of Graves' disease unresponsive to traditional drugs.

引用

页码：678 / 684

页数：7

共 69 条

[1] A systematic review of drug therapy for Graves' hyperthyroidism [J].

Abraham, P ;

Avenell, A ;

Park, CM ;

Watson, WA ;

Bevan, JS .

EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2005, 153 (04) :489-498

[2] ANTITHYROID DRUGS AND GRAVES-DISEASE - A PROSPECTIVE RANDOMIZED EVALUATION OF THE EFFICACY OF TREATMENT DURATION [J].

ALLANNIC, H ;

FAUCHET, R ;

ORGIAZZI, J ;

MADEC, AM ;

GENETET, B ;

LORCY, Y ;

LEGUERRIER, AM ;

DELAMBRE, C ;

DERENNES, V .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1990, 70 (03) :675-679

[3] Systematic review: Agranulocytosis induced by nonchemotherapy drugs [J].

Andersohn, Frank ;

Konzen, Christine ;

Garbe, Edeltraut .

ANNALS OF INTERNAL MEDICINE, 2007, 146 (09) :657-665

[4] Systematic review: Efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura [J].

Arnold, Donald M. ;

Dentali, Francesco ;

Crowther, Mark A. ;

Meyer, Ralph M. ;

Cook, Richard J. ;

Sigouin, Christopher ;

Fraser, Graeme A. ;

Lim, Wendy ;

Kelton, John G. .

ANNALS OF INTERNAL MEDICINE, 2007, 146 (01) :25-W5

[5]

Bahn Rebecca S, 2009, Thyroid, V19, P673, DOI 10.1089/thy.2009.0169

[6] Extrathyroidal actions of antithyroid thionamides [J].

Bandyopadhyay, U ;

Biswas, K ;

Banerjee, RK .

TOXICOLOGY LETTERS, 2002, 128 (1-3) :117-127

[7] Epidemiology of functional autonomy [J].

Bauch, K .

EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 1998, 106 :S16-S22

[8] AN ANTI-NEUTROPHIL ANTIBODY ASSOCIATED WITH A PROPYLTHIOURACIL-INDUCED LUPUS-LIKE SYNDROME [J].

BERKMAN, EM ;

ORLIN, JB ;

WOLFSDORF, J .

TRANSFUSION, 1983, 23 (02) :135-138

[9] Resumption of methimazole after 131I therapy of hyperthyroid diseases:: effect on thyroid function and volume evaluated by a randomized clinical trial [J].

Bonnema, SJ ;

Bennedbæk, FN ;

Gram, J ;

Veje, A ;

Marving, J ;

Hegedüs, L .

EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2003, 149 (06) :485-492

[10] An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab [J].

Boye, J ;

Elter, T ;

Engert, A .

ANNALS OF ONCOLOGY, 2003, 14 (04) :520-535

← 1 2 3 4 5 6 7 →